2
Clinical Trials associated with HM-002-1005A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple- Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS1005 in Participants With Type 2 Diabetes
The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes
HM-002-1005 - A Phase 1, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Subjects With Type 2 Diabetes Mellitus
The purposes of this study are to:
* Evaluate the safety and tolerability of the study drug.
* Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them.
* Measure the amount of glucose (blood sugar) and a substance called C-peptide in the bloodstream after receiving the study drug.
Researchers will compare the study drug to a placebo (a look-alike substance that contains no drug).
Participants will:
* Stay 5 days and 4 nights or 6 days and 5 nights at the research site, and have a follow-up phone call 7 days after leaving the research site.
* Take one (1) dose of the study drug or placebo
* Have blood taken to measure the amount of study drug and its breakdown product and the levels of glucose and C-peptide
* Have safety tests such as vital sign, ECGs, and glucose measurements
100 Clinical Results associated with HM-002-1005
100 Translational Medicine associated with HM-002-1005
100 Patents (Medical) associated with HM-002-1005
100 Deals associated with HM-002-1005